Scandion Oncology News, January 2020
The first phase 2 study with SCO-101 in combination with chemotherapy: Scandion Oncology has previously announced that all necessary permissions to initiate the clinical phase 2 study with SCO-101 in patients with chemotherapy resistant colorectal cancer were obtained late 2019. In addition, we have signed contracts with Herlev Hospital in Copenhagen and TFS International who will be our Clinical Research Organization (CRO) for the study. When the first three patients have been treated at Herlev Hospital, the Department of Oncology, then University Hospital in Aalborg, Denmark, will join